Reduction of serum advanced glycosylation end products-peptides and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats

Journal of China Pharmaceutical University

Volumn 36, Issue 6, 2005, Pages 559-562

  Sun, Zi Lin ^a,b   Liu, Nai Feng ^b   Sun, Yu Yan ^b   Wei, Qiong ^b   Zhang, Yong ^c   Sun, Gui Ju ^c   Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

AGE peptide; Diabetes mellitus; Monocyte chemoattractant protein 1; Rosiglitazone maleate

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; DRUG VEHICLE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; ROSIGLITAZONE; STREPTOZOCIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW INJECTION ANALYSIS; LIPID DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RANDOMIZATION; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 30544448497     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications[J]. Physiol Res, 2004, 53(2):131-142.
2. Sun ZL, Liu NF, Liu BC, Chinese source. (Chin J Endocrinol Metab), 2000,16(4):250-253.
3. Sun ZL, Liu NF, Liu BC, Chinese source. (Chin J Nephrol), 2000,16(4):262-263.
4. Guo XH, Liu ZH, Li H, Chinese source. 2000,9(4):351-355.
5. Balfour JA, Plosker GL. Rosiglitazone[J]. Drugs, 1999,57(6):921-930.
6. Viberti GC. Rosiglitazone: potential beneficial impact on cardiovascular disease[J]. Int J Clin Pract, 2003,57(2):128-134.
7. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes[J]. J Hum Hypertens, 2003,17(1):7-12.
8. Blondeau B, Auril I, Duchene B, Breant B. Endocrine pancreas development is altered in foetuses from rats previously showing intrauterine growth retardation in pesponse to malnutrition [J]. Diabetologia, 2002,45:394-401.
9. Wang BR, Liu NF. Gene expression of monocyte chemoattractant protein-1 in human monocytes by exposure to advanced glycosylation end products[J]. Acta Pharmacol Sin, 2001,22(1):67-70.
10. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products[J]. Diabetes, 2004,53(10):2 662-2 668.
11. Yu XY, Li C, Zhang XY, Chinese source. [J Jilin Univ (Med Ed)], 2003,29(3):255-257.
12. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone[J]. J Clin Endocrinol Metab, 2004,89(6):2 728-2 735.
13. Chiarelli F, Cipollone F, Mohn A, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes[J]. Diabetes Care, 2002,25(10):1 829-1 834.
14. Petrkova J, Szotkowska J, Hermanova Z, et al. Monocyte chemoattractant protein-1 in patients with peripheral arterial disease [J]. Mediators Inflamm, 2004,13(1):39-43.